Core Viewpoint - The company Guangkang Biochemical announced a share reduction plan by specific shareholders, which may indicate a potential shift in investor sentiment and could impact the stock price in the near term [1][10]. Shareholder Reduction Plans - Specific shareholders, including Huatuo Zhiying No. 2, Huatuo Zhiyuan No. 3, and Ruihong Kaiyin No. 1, plan to reduce their holdings within three months from the announcement date through centralized bidding and block trading [1][4]. - Huatuo Zhiying No. 2 and Huatuo Zhiyuan No. 3 plan to collectively reduce up to 1.3198 million shares, accounting for 1.7835% of the total share capital, while Ruihong Kaiyin No. 1 plans to reduce up to 1.98 million shares, representing 2.6757% of the total share capital [4][6]. Historical Context of Share Reductions - The shareholders are preparing for a "clearance-style" reduction, with Ruihong Kaiyin No. 1 having previously announced a similar reduction plan in October 2025, which was not executed [7]. - Huatuo Zhiying No. 2 and Huatuo Zhiyuan No. 3 had also announced a reduction plan in September 2025, resulting in a decrease in Huatuo Zhiyuan No. 3's holding from 0.6022% to 0.5884% [7]. Company Background - Guangkang Biochemical is a national high-tech enterprise specializing in the research, production, and sales of pesticide active ingredients, intermediates, and formulations [8]. - The company received a warning letter from the Guangdong Securities Regulatory Bureau a month prior to the announcement of the share reduction [10]. Financial Management Issues - From July 2023 to August 2025, the company used raised funds for cash management, purchasing 179 financial products, of which 158 were non-principal guaranteed products. The company did not adequately disclose the risks associated with these investments in its reports [10]. Stock Performance - The timing of the reduction announcement coincides with a nearly 20% rebound in the company's stock price from February 6 to February 11. Following the announcement, the stock initially dipped but later rebounded, closing up over 5% [10].

智通财经APP讯，广康生化(300804.SZ)发布公告，特定股东共青城华拓至盈贰号投资合伙企业(有限合 伙)(以下简称"华拓至盈贰号")、深圳市华拓至远叁号投资企业(有限合伙)(以下合称"华拓至远叁号")以 及共青城瑞宏凯银壹号股权投资基金合伙企业(有限合伙)(以下简称"瑞宏凯银壹号")计划自本公告披露 之日起三个交易日后的三个月内，通过集中竞价和大宗交易方式减持公司股份。其中，华拓至盈贰号和 华拓至远叁号计划合计减持不超过131.98万股，即不超过公司总股本的1.7835%；瑞宏凯银壹号计划减 持不超过198万股，即不超过公司总股本的2.6757%。 ...

广康生化（300804）(300804.SZ)发布公告，特定股东共青城华拓至盈贰号投资合伙企业(有限合伙)(以 下简称"华拓至盈贰号")、深圳市华拓至远叁号投资企业(有限合伙)(以下合称"华拓至远叁号")以及共青 城瑞宏凯银壹号股权投资基金合伙企业(有限合伙)(以下简称"瑞宏凯银壹号")计划自本公告披露之日起 三个交易日后的三个月内，通过集中竞价和大宗交易方式减持公司股份。其中，华拓至盈贰号和华拓至 远叁号计划合计减持不超过131.98万股，即不超过公司总股本的1.7835%；瑞宏凯银壹号计划减持不超 过198万股，即不超过公司总股本的2.6757%。 ...

Group 1 - The core point of the article is that Guangkang Biochemical announced the pledge of 1 million shares by its controlling shareholder, Cai Danqun, to Shenzhen Shendan Credit Financing Guarantee Co., Ltd. for personal funding needs [2] - The pledged shares represent 3.87% of Cai Danqun's total holdings and 1.35% of the company's total share capital [2] - The registration date for the pledge is February 10, 2026 [2]

Group 1 - The core announcement from Guangdong Guangkang Biochemical Technology Co., Ltd. involves specific shareholders planning to reduce their stakes in the company through centralized bidding and block trading within three months from the announcement date [1] - The shareholders, including Qiongcheng Huatuo Zhiying No. 2 Investment Partnership and Shenzhen Huatuo Zhiyuan No. 3 Investment Enterprise, plan to collectively reduce their holdings by up to approximately 1.7835% of the total share capital, which amounts to about 132,000 shares [1] - Another shareholder, Qiongcheng Ruihong Kaiyin No. 1 Equity Investment Fund Partnership, intends to reduce its stake by up to 198,000 shares, representing about 2.68% of the total share capital [1] Group 2 - The news also highlights a significant development in the video generation industry, where a Chinese video model is being referred to as the "strongest on earth," capable of generating 15-second videos for commercial delivery with just a few prompts [1] - This advancement has led to a surge in stock prices for film and television companies, indicating a positive market reaction to the technological innovation [1]

格隆汇2月11日丨广康生化(300804.SZ)公布，特定股东共青城华拓至盈贰号投资合伙企业（有限合伙） （简称"华拓至盈贰号"）、深圳市华拓至远叁号投资企业（有限合伙）（合称"华拓至远叁号"）以及共 青城瑞宏凯银壹号股权投资基金合伙企业（有限合伙）（简称"瑞宏凯银壹号"）计划自本公告披露之日 起三个交易日后的三个月内，通过集中竞价和大宗交易方式减持公司股份。其中，华拓至盈贰号和华拓 至远叁号计划合计减持不超过131.98万股，即不超过公司总股本的1.7835%；瑞宏凯银壹号计划减持不 超过198万股，即不超过公司总股本的2.6757%。 ...

证券代码：300804 证券简称：广康生化 公告编号：2026-004 股东深圳市华拓至远叁号投资企业（有限合伙）、共青城华拓至盈贰号投资合 伙企业（有限合伙）、共青城瑞宏凯银壹号股权投资基金合伙企业（有限合伙）保 证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 广东广康生化科技股份有限公司（以下简称"公司"或"发行人"）特定股东共 青城华拓至盈贰号投资合伙企业（有限合伙）（以下简称"华拓至盈贰号"）、深圳 市华拓至远叁号投资企业（有限合伙）（以下合称"华拓至远叁号"）以及共青城瑞 宏凯银壹号股权投资基金合伙企业（有限合伙）（以下简称"瑞宏凯银壹号"）计划 自本公告披露之日起三个交易日后的三个月内，通过集中竞价和大宗交易方式减持公 司股份。其中，华拓至盈贰号和华拓至远叁号计划合计减持不超过 1,319,800 股，即 不超过公司总股本的 1.7835%；瑞宏凯银壹号计划减持不超过 1,980,000 股，即不超 过公司总股本的 2.6757%。 公司近日收到华拓至盈贰号、华拓至远叁号及瑞宏凯银壹号 ...

证券代码：300804 证券简称：广康生化 公告编号：2026-003 广东广康生化科技股份有限公司 （一）本次股份质押基本情况 | 深圳市深 | 2026 | 年 | 至办理解除 | 个人 | 是（首发前限 | 担增信融 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 蔡丹群 | 是 | 100.00 | 3.87% | 1.35% | 否 | 2 | 月 | 10 | 质押登记手 | 资金 | 售股） | 资担保有 | 日 | 续之日止 | 需求 | | 限公司 | | | | | | | | | | | | | | | | （二）股东股份累计质押情况 截至本公告披露日，公司控股股东、实际控制人及其一致行动人所持股份质 押情况如下： | 蔡丹群 | 2,582.00 | 34.89% | 200.00 | 300.00 | 11.62% | 4.05% | 300.00 | 100% | 2,282.00 | 100 ...

广东广康生化科技股份有限公司 证券代码：300804 证券简称：广康生化 公告编号：2026-002 一、股东减持情况 （一）股东减持股份情况 关于特定股东减持股份计划期限届满暨实施情况的公告 股东共青城瑞宏凯银壹号股权投资基金合伙企业（有限合伙）保证向本公司 提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 广东广康生化科技股份有限公司（以下简称"公司"）于 2025 年 10 月 15 日在 巨潮资讯网（www.cninfo.com.cn）披露了《关于特定股东减持股份预披露公告》（公 告编号：2025-048），公司股东共青城瑞宏凯银壹号股权投资基金合伙企业（有限合 伙）（以下简称"瑞宏凯银壹号"）计划于减持计划公告之日起三个交易日后的三个 月内（即 2025 年 10 月 18 日-2026 年 1 月 17 日）以集中竞价交易或大宗交易方式减 持公司股份累计不超过 1,980,000 股，即不超过本公司总股本的 2.6757%。 截至 2026 年 1 月 17 日，上述减持计划期限已届满。公司已收到上述股东发来的 ...

Core Insights - The expiration of the compound patent for Pyraclostrobin in China has led to a surge in domestic interest, with companies increasing registration, production, and promotion efforts [1][6] - As of 2024, there are 62 registered Pyraclostrobin products in China, including 32 active ingredients and 30 formulations, primarily targeting wheat and peanut crops [1][6] - The global market for Pyraclostrobin has seen significant growth, with sales expected to rise from $973 million in 2015 to $2.014 billion by 2024, and projected to reach $2.172 billion by 2025 [5][11] Industry Overview - Pyraclostrobin, developed by Bayer in 2004, is a broad-spectrum fungicide known for its low toxicity and effectiveness against various plant diseases [2][3] - It is particularly effective against diseases affecting cereals and legumes, making it a key product in the global fungicide market, holding an 8% market share [3][5] Market Dynamics - The Chinese market for Pyraclostrobin is expanding rapidly due to the high incidence of wheat diseases, particularly Fusarium head blight, which can cause yield losses of 10% to 20% in epidemic years [7][11] - The area affected by Fusarium head blight in China is projected to reach 15 million acres in 2024, an increase of 6 million acres from 2023 [7][8] Competitive Landscape - Major companies in the Pyraclostrobin sector include Hailir, Anhui Jiuyi, Nantong Taihe, and Guangdong Guokang, among others, with many expanding production capacity [9][10] - Hailir reported a revenue of 3.391 billion yuan in the first nine months of 2025, a 5.5% increase year-on-year, indicating strong market performance [10] Future Trends - The demand for Pyraclostrobin is expected to continue rising due to increasing occurrences of wheat diseases and advancements in application methods [11] - The market is becoming increasingly competitive, with potential oversupply leading to price fluctuations, necessitating companies to optimize production and enhance brand presence [12] - The trend towards formulation mixtures is anticipated to grow, as combining Pyraclostrobin with other chemicals can delay resistance development and enhance efficacy [13]